Long-term treatment of uterine fibroids with ulipristal acetate ☆ - Wikidata - wikimedia - TriplyDB

Long-term treatment of uterine fibroids with ulipristal acetate ☆

Long-term treatment of uterine fibroids with ulipristal acetate ☆

http://www.wikidata.org/entity/Q28235922

about

Long-term intermittent pharmacological therapy of uterine fibroids - a possibility to avoid hysterectomy and its negative consequences The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids Ulipristal acetate for fibroids Selective progesterone receptor modulator (SPRM) ulipristal acetate (UPA) and its effects on the human endometrium.Successful pregnancy after treatment with ulipristal acetate for uterine fibroids Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues.Role of nuclear progesterone receptor isoforms in uterine pathophysiology.The conservative and interventional treatment of fibroids Presentation and treatment of uterine leiomyoma in adolescence: a systematic review.Clinical utility of ulipristal acetate for the treatment of uterine fibroids: current evidence.Expulsion of a uterine myoma in a patient treated with ulipristal acetate.Urinary retention and uterine leiomyomas: a case series and systematic review of the literature.Tissue-specific stem cells in the myometrium and tumor-initiating cells in leiomyoma.Ulipristal Acetate Inhibits Progesterone Receptor Isoform A-Mediated Human Breast Cancer Proliferation and BCl2-L1 Expression.Effects of Combination of Estradiol with Selective Progesterone Receptor Modulators (SPRMs) on Human Breast Cancer Cells In Vitro and In Vivo.Safety after extended repeated use of ulipristal acetate for uterine fibroids Endocrinology of uterine fibroids: steroid hormones, stem cells, and genetic contribution.Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies Uterine fibroid shrinkage after short-term use of selective progesterone receptor modulator or gonadotropin-releasing hormone agonist.An update on the pharmacological management of adenomyosis.Selective progesterone receptor modulators: a class with multiple actions and applications in reproductive endocrinology, and gynecology.Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids.Ulipristal acetate for uterine fibroids: a systematic review and meta-analysis.The use of selective progestin receptor modulators (SPRMs) and more specifically ulipristal acetate in the practice of gynaecology.An observation study of the clinical evaluation of symptom relief and side effects associated with taking ulipristal acetate (esmya) including its effect on pre-menstrual syndrome.Estrogen Receptors and Signaling in Fibroids: Role in Pathobiology and Therapeutic Implications.Selective progesterone receptor modulators (SPRMs) for uterine fibroids.Proteoglycans in Leiomyoma and Normal Myometrium: Abundance, Steroid Hormone Control, and Implications for Pathophysiology.Uterine fibroid management: from the present to the future.Choice of primary outcomes evaluating treatment for heavy menstrual bleeding.Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids.Ulipristal acetate for pre-operative treatment of moderate-to-severe uterine fibroids in women of reproductive age in The Netherlands: cost minimization analysis and budget impact analysis.Molecular and clinical attributes of uterine leiomyomas.Updated approaches for management of uterine fibroids Economic impact of ulipristal acetate on surgical procedures for uterine fibroids in France Selective progesterone receptor modulators for fertility preservation in women with symptomatic uterine fibroids.Uterine fibroids - what's new?Adverse obstetric outcomes in pregnant women with uterine fibroids in China: A multicenter survey involving 112,403 deliveries.Repeated intermittent ulipristal acetate in the treatment of uterine fibroids: a cost-effectiveness analysis.

P2860

Q26751927-81188C44-92F9-4E55-A67B-A199DB1B41FA Q26998672-9D38009F-14C3-472A-92DB-6A572110E5E1 Q28080041-E7E7ABA3-4D7C-4C7C-A1CA-37983A1DD1AF Q33589684-C42FC34F-AB38-4CC1-A6A6-1ECBB1536317 Q34038083-40EF77B1-7186-4DE2-A349-E13C238E5D72 Q34447552-F1A44F68-5EFF-4D01-A45C-FA3CEE2ED3C2 Q34448400-FA659218-58B3-4F55-B63E-71E865872258 Q34982023-177508EB-5C1D-4860-B201-741DB8390A84 Q35021066-5F8FFDAA-B5AE-4585-929E-0F5E994CA888 Q35240186-480A06E4-8901-46B9-9609-4FE9CB84C316 Q35512180-90A12AE8-C4D9-4D54-B48C-E763D7D75C97 Q35573858-1A0660FD-E69D-4B81-BA62-E3FB6DCF0E60 Q35617315-B111E3B1-63A0-4E65-AAC8-8EFEA09CB697 Q35810608-4EA20F96-453C-42A3-AF37-1A0482ED0C79 Q35969254-716608FA-7A1B-47F0-AAB3-AF4EA7A0F863 Q36299562-9BAA66D9-A604-413B-95D9-09FB6971CBBC Q36525065-AE96B276-B392-42BD-B07C-2DEE93BF25A6 Q37186618-63E589B2-FA05-4D37-8155-0A185BA16AF4 Q37647346-CF0A3703-A828-4303-A842-4742A71918DD Q38246723-D34DBAA1-4E1E-4BDF-9EF5-ED9D9BCA1186 Q38252992-B047C14E-9A28-4317-9909-FA7323EDC59F Q38378813-1F80D53B-67CC-46FC-8590-995869A933D7 Q38634268-749B9E10-0255-4672-AE6B-20ED253DE5D0 Q38676367-AB797FC6-8F35-4B95-A395-82616A097B32 Q38789764-361F228E-1BA2-4124-BCDB-568464558575 Q38792320-259CBBCB-7791-4D3F-9188-3B7447274D73 Q38819001-B15B4472-41BA-4214-B076-453D6F101210 Q38831211-59DC3D31-FD08-4A05-A6E8-C71931EB7896 Q38837038-CEE223B4-BF31-4AB8-BE68-2D9EDC27C69A Q38848136-BD989B48-84E4-4AFE-8A5B-28C157DD4714 Q38980489-53F318F7-F098-420A-B458-7A6B48A1779E Q39080721-17171881-C05F-43FD-A63B-53F1BC72B85B Q39244598-B29C74A8-CA1C-4367-B3CF-C527D4458E93 Q39400414-5BEF573C-F2D7-4AA5-9302-611394E0E417 Q41385417-A96B8FDC-6F08-468B-AAC6-A4BD7ABADE5A Q41581866-2CB185CB-83FF-4D59-826F-52F119827577 Q46560230-20B8FC1E-0679-4BDE-B1B9-366949234345 Q47135445-AEF8A0CC-87B5-449A-9AFD-5CF69C4D18CB Q47136481-C44ACCFA-55FF-406C-8DA8-3BBBB04A23ED Q47160345-C69C103C-29C8-4AB6-9FBD-B4B2F2ADB5F4

P2860

Long-term treatment of uterine fibroids with ulipristal acetate ☆

http://www.wikidata.org/entity/Q28235922

description

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

artículu científicu espublizáu en 2014

@ast

im Juni 2014 veröffentlichter wissenschaftlicher Artikel

@de

scientific article (publication date: June 2014)

@en

vedecký článok (publikovaný 2014-06)

@sk

vědecký článek publikovaný v roce 2014

@cs

wetenschappelijk artikel (gepubliceerd in 2014-06)

@nl

наукова стаття, опублікована в червні 2014

@uk

مقالة علمية (نشرت في يونيو 2014)

@ar

name

Long-term treatment of uterine fibroids with ulipristal acetate ☆

@ast

Long-term treatment of uterine fibroids with ulipristal acetate ☆

@en

Long-term treatment of uterine fibroids with ulipristal acetate ☆

@nl

type

label

Long-term treatment of uterine fibroids with ulipristal acetate ☆

@ast

Long-term treatment of uterine fibroids with ulipristal acetate ☆

@en

Long-term treatment of uterine fibroids with ulipristal acetate ☆

@nl

prefLabel

Long-term treatment of uterine fibroids with ulipristal acetate ☆

@ast

Long-term treatment of uterine fibroids with ulipristal acetate ☆

@en

Long-term treatment of uterine fibroids with ulipristal acetate ☆

@nl

P1433

Q28235922-8DF81B47-847A-4DA2-863B-D44C98B59008

P1476

Q28235922-4160384F-551C-48B3-BA60-54E50A3BFB03

P2093

Q28235922-0A6785C3-1E3D-4FDF-8EA3-F1C4FAD67CAD

Q28235922-0D1F5A1F-F02F-4E9C-A2EF-09BF807B8900

Q28235922-2C74E3F0-3DAB-43AC-A39B-145829429F98

Q28235922-37A05DE9-6E96-42E9-A8D1-C09FE0D8F462

Q28235922-6EB92FD8-590A-4F81-94E7-82D7B2128F61

Q28235922-7E42490B-03E9-4D3E-80A9-3EEF2C7329C3

Q28235922-99CE6400-F2C3-4BF7-BDE7-0A2DAFF19081

Q28235922-9A0A8564-97FB-43A3-8F2F-AA0FF7073B5A

Q28235922-9E1FD924-59EE-47AC-AA46-D54F46971CE3

Q28235922-A1674DE4-34E6-42DE-A692-679342A26827

P304

Q28235922-E7D80B80-D519-4738-8111-9C7BD01249A4

P31

Q28235922-151E66DF-71C6-4E64-AD75-4A91071BBF13

P3181

Q28235922-ABE00BE5-EC3F-4A7D-B0B6-E197F37C3EC3

P356

Q28235922-38BA2B49-0747-4F2F-BC7E-3952A0AD8AE3

P407

Q28235922-578F40F0-F5FA-412B-A6D4-DABB8BAEFE27

P433

Q28235922-9475EDE5-51C9-40CE-8E7D-3EA5490C82FF

P478

Q28235922-B30F7EAA-D97A-480B-AB5E-8A1D9141007C

P50

Q28235922-32E06429-FDCC-45E9-A0A6-B1734BB1E681

P577

Q28235922-5246D762-3079-4967-A4C7-7402DC18A103

P5875

Q28235922-9510321D-6B5F-4AFD-A1AF-3176CE10FD26

P698

Q28235922-36B6F77F-2AFB-4F46-A0E3-B3C221095E05

P3181

P356

J.FERTNSTERT.2014.02.008

P1433

Fertility and Sterility

P1476

Long-term treatment of uterine fibroids with ulipristal acetate ☆

@en

P2093

Bart C J M Fauser

http://www.w3.org/2001/XMLSchema#string

David H Barlow

http://www.w3.org/2001/XMLSchema#string

Elke Bestel

http://www.w3.org/2001/XMLSchema#string

Ernest Loumaye

http://www.w3.org/2001/XMLSchema#string

Francisco Vázquez

http://www.w3.org/2001/XMLSchema#string

Ian Osterloh

http://www.w3.org/2001/XMLSchema#string

Janusz Tomaszewski

http://www.w3.org/2001/XMLSchema#string

Kazem Nouri

http://www.w3.org/2001/XMLSchema#string

Olivier Donnez

http://www.w3.org/2001/XMLSchema#string

Philippe Bouchard

http://www.w3.org/2001/XMLSchema#string

P304

1565-73.e1-18

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1905670

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.FERTNSTERT.2014.02.008

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260759948

http://www.w3.org/2001/XMLSchema#string

P698

24630081

http://www.w3.org/2001/XMLSchema#string